Abstract
Recent studies implicate specific PKC isoforms in the insulin-signaling cascade. Insulin activates PKCs α, βII, δ and ζ in several cell types. In addition, as will be documented in this review, certain members of the PKC family may also be activated and act upstream of PI3 and MAP kinases. Each of these isoforms has been shown one way or another either to mimic or to modify insulin-stimulated effects in one or all of the insulin-responsive tissues. Moreover, each of the isoforms has been shown to be activated by insulin stimulation or conditions important for effective insulin stimulation. Studies attempting to demonstrate a definitive role for any of the isoforms have been performed on different cells, ranging from appropriate model systems for skeletal muscle, liver and fat, such as primary cultures, and cell lines and even in vivo studies, including transgenic mice with selective deletion of specific PKC isoforms. In addition, studies have been done on certain expression systems such as CHO or HEK293 cells, which are far removed from the tissues themselves and serve mainly as vessels for potential protein-protein interactions. Thus, a clear picture for many of the isoforms remains elusive in spite of over two decades of intensive research. The recent intrusion of transgenic and precise molecular biology technologies into the research armamentarium has opened a wide range of additional possibilities for direct involvement of individual isoforms in the insulin signaling cascade. As we hope to discuss within the context of this review, whereas many of the long sought-after answers to specific questions are not yet clear, major advances have been made in our understanding of precise roles for individual PKC isoforms in mediation of insulin effects. In this review, in which we shall focus our attention on isoforms in the conventional and novel categories, a clear case will be made to show that these isoforms are not only expressed but are importantly involved in regulation of insulin metabolic effects.
| Original language | English |
|---|---|
| Pages (from-to) | 32-47 |
| Number of pages | 16 |
| Journal | Molecular Genetics and Metabolism |
| Volume | 89 |
| Issue number | 1-2 |
| DOIs | |
| State | Published - Sep 2006 |
Bibliographical note
Funding Information:The authors acknowledge the following sources of support. SRS was supported in part by the Russell Berrie Foundation and D-Cure, Diabetes Care in Israel, the Chief Scientist’s Office of the Israel Ministry of Health, and by the Sorrell Foundation. SRS is the incumbent of the Louis Fisher Chair in Cellular Pathology. DRC was supported by the Medical Research Service of the Department of Veterans Affairs and NIH DK 54393.
Funding
The authors acknowledge the following sources of support. SRS was supported in part by the Russell Berrie Foundation and D-Cure, Diabetes Care in Israel, the Chief Scientist’s Office of the Israel Ministry of Health, and by the Sorrell Foundation. SRS is the incumbent of the Louis Fisher Chair in Cellular Pathology. DRC was supported by the Medical Research Service of the Department of Veterans Affairs and NIH DK 54393.
| Funders | Funder number |
|---|---|
| Diabetes Care in Israel | |
| Russell Berrie Foundation | |
| Sorrell Foundation | |
| National Institutes of Health | |
| National Institute of Diabetes and Digestive and Kidney Diseases | R01DK054393 |
| U.S. Department of Veterans Affairs | |
| Office of the Chief Scientist, Ministry of Health |
Keywords
- Conventional and novel PKCs
- Insulin signaling
- Tyrosine phosphorylation